Статті в журналах з теми "NSCLCs"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "NSCLCs".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Awad, Mark M., Geoffrey R. Oxnard, David M. Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C. Heng, et al. "MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression." Journal of Clinical Oncology 34, no. 7 (March 1, 2016): 721–30. http://dx.doi.org/10.1200/jco.2015.63.4600.
Повний текст джерелаMaitra, Radhashree, Parth Malik, and Tapan Kumar Mukherjee. "Targeting Estrogens and Various Estrogen-Related Receptors against Non-Small Cell Lung Cancers: A Perspective." Cancers 14, no. 1 (December 24, 2021): 80. http://dx.doi.org/10.3390/cancers14010080.
Повний текст джерелаFarago, Anna F., Martin S. Taylor, Robert C. Doebele, Viola W. Zhu, Shivaani Kummar, Alexander I. Spira, Theresa A. Boyle, et al. "Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an NTRK Gene Fusion." JCO Precision Oncology, no. 2 (November 2018): 1–12. http://dx.doi.org/10.1200/po.18.00037.
Повний текст джерелаNowinska, Jablonska, Pawelczyk, Piotrowska, Partynska, Gomulkiewicz, Ciesielska, et al. "Expression of Irisin/FNDC5 in Cancer Cells and Stromal Fibroblasts of Non-small Cell Lung Cancer." Cancers 11, no. 10 (October 11, 2019): 1538. http://dx.doi.org/10.3390/cancers11101538.
Повний текст джерелаYan, Dan, H. Shelton Earp, Deborah DeRyckere, and Douglas K. Graham. "Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer." Cancers 13, no. 22 (November 11, 2021): 5639. http://dx.doi.org/10.3390/cancers13225639.
Повний текст джерелаLandre, Thierry, Gregoire Justeau, Jean-baptiste Assié, Kader Chouahnia, Chérifa Taleb, Christos Chouaid, and Boris Duchemann. "Anti PD-(L)1 in KRAS mutant advanced nsclcs: A meta-analysis of randomized controlled trials." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 9025. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9025.
Повний текст джерелаLiu, Jia-Chun, Suresh Narva, Kang Zhou, and Wen Zhang. "A Review on the Antitumor Activity of Various Nitrogenous-based Heterocyclic Compounds as NSCLC Inhibitors." Mini-Reviews in Medicinal Chemistry 19, no. 18 (November 29, 2019): 1517–30. http://dx.doi.org/10.2174/1389557519666190312152358.
Повний текст джерелаWang, Hsiang-Sheng, Chien-Ying Liu, Sheng-Chi Hsu, Shih-Chiang Huang, Tsai-Hsien Hung, Kwai-Fong Ng, and Tse-Ching Chen. "A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan." International Journal of Molecular Sciences 23, no. 10 (May 21, 2022): 5789. http://dx.doi.org/10.3390/ijms23105789.
Повний текст джерелаGasparini, Pierluigi, Luciano Cascione, Lorenza Landi, Stefania Carasi, Francesca Lovat, Carmelo Tibaldi, Greta Alì, et al. "microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers." Proceedings of the National Academy of Sciences 112, no. 48 (November 16, 2015): 14924–29. http://dx.doi.org/10.1073/pnas.1520329112.
Повний текст джерелаSerresi, Michela, Bjorn Siteur, Danielle Hulsman, Carlos Company, Matthias J. Schmitt, Cor Lieftink, Ben Morris, et al. "Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities." Journal of Experimental Medicine 215, no. 12 (November 28, 2018): 3115–35. http://dx.doi.org/10.1084/jem.20180801.
Повний текст джерелаPassaro, Antonio, Ilaria Attili, Alessandra Rappa, Davide Vacirca, Alberto Ranghiero, Caterina Fumagalli, Juliana Guarize, et al. "Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations." Cancers 13, no. 9 (April 30, 2021): 2172. http://dx.doi.org/10.3390/cancers13092172.
Повний текст джерелаHellmann, Matthew David, Francisco Sanchez-Vega, Konnor La, Hira Rizvi, Darragh Halpenny, Andrew Plodkowski, Niamh Long, et al. "Molecular determinants of response and resistance to anti-PD-(L)1 blockade in patients with NSCLC profiled with targeted next-generation sequencing (NGS)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 9015. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9015.
Повний текст джерелаSkrzypski, Marcin Tomasz, Amelia Szymanowska-Narloch, Ewa Jassem, Michał Marczyk, Joanna Polanska, Wojciech Biernat, Witold Rzyman, Agnieszka Maciejewska, Ryszard Pawlowski, and Jacek Jassem. "Prognostic value of NK and T-lymphocytes markers in operable non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 11556. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.11556.
Повний текст джерелаKaplan, Benjamin G., Richard S. Huang, Lucas Dennis, Lee A. Albacker, Garrett M. Frampton, Ethan S. Sokol, and Smruthy Sivakumar. "Abstract 753: Comprehensive genomic profiling (CGP) reveals site-specific enrichment of immunotherapy biomarkers and targetable alterations in non-small cell lung cancer (NSCLC) metastasis." Cancer Research 82, no. 12_Supplement (June 15, 2022): 753. http://dx.doi.org/10.1158/1538-7445.am2022-753.
Повний текст джерелаLypova, Nadiia, Susan M. Dougherty, Lilibeth Lanceta, Jason Chesney, and Yoannis Imbert-Fernandez. "PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs." Cells 10, no. 7 (July 3, 2021): 1679. http://dx.doi.org/10.3390/cells10071679.
Повний текст джерелаRicciuti, Biagio, Kathryn Cecilia Arbour, Joao Victor Machado Alessi, Navin Mahadevan, James Lindsay, Rileen Sinha, Natalie I. Vokes, et al. "Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 9018. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9018.
Повний текст джерелаOhashi, Kadoaki, Lecia V. Sequist, Martin Sos, Xi Chen, Charles M. Rudin, Teresa Moran, Maria E. Arcila, et al. "Characteristics of NSCLCs harboring NRAS mutations." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 7532. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.7532.
Повний текст джерелаRocco, Danilo, Ciro Battiloro, Luigi Della Gravara, and Cesare Gridelli. "Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond." Reviews on Recent Clinical Trials 14, no. 2 (May 31, 2019): 120–28. http://dx.doi.org/10.2174/1574887114666181205155211.
Повний текст джерелаNambirajan, Aruna, Varsha Singh, Nishu Bhardwaj, Saurabh Mittal, Sunil Kumar, and Deepali Jain. "SMARCA4/BRG1–Deficient Non–Small Cell Lung Carcinomas: A Case Series and Review of the Literature." Archives of Pathology & Laboratory Medicine 145, no. 1 (April 9, 2020): 90–98. http://dx.doi.org/10.5858/arpa.2019-0633-oa.
Повний текст джерелаRocha, Pedro, Jiexin Zhang, Raquel Laza-Briviesca, Alberto Cruz-Bermúdez, Katsuhiro Yoshimura, Carmen Behrens, Apar Pataer, et al. "Abstract 6152: Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC." Cancer Research 82, no. 12_Supplement (June 15, 2022): 6152. http://dx.doi.org/10.1158/1538-7445.am2022-6152.
Повний текст джерелаChandra, Raghav, Josiah Flaming, Aiden Nguyen, Michael Peyton, Amit Das, Boning Gao, Steven Horrigan, Rolf Brekken, and John Minna. "919 Tegavivint reduces the immunosuppressive macrophage phenotype in a preclinical co-culture model of the non-small cell lung cancer tumor microenvironment." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A964. http://dx.doi.org/10.1136/jitc-2021-sitc2021.919.
Повний текст джерелаChang, Jia-Ming, Kam-Hong Kam, Wen-Ying Chao, Pei-Wen Zhao, Shu-Hsin Chen, Hui-Chen Chung, Yi-Zhen Li, Jin-Yi Wu, and Ying-Ray Lee. "Berberine Derivatives Suppress Cellular Proliferation and Tumorigenesis In Vitro in Human Non-Small-Cell Lung Cancer Cells." International Journal of Molecular Sciences 21, no. 12 (June 13, 2020): 4218. http://dx.doi.org/10.3390/ijms21124218.
Повний текст джерелаAlessi, Joao Victor Machado, Carolyn Glass, Biagio Ricciuti, Liam F. Spurr, Lynette M. Sholl, and Mark M. Awad. "Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 9577. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.9577.
Повний текст джерелаGutierrez, Catherine, Biagio Ricciuti, Joao Victor Machado Alessi, Federica Pecci, Adriana Paula de Castro Barrichello, Victor R. Vaz, Lynette M. Sholl, and Mark M. Awad. "Impact of STK11 copy loss on clinical outcomes to PD-(L)1 blockade in non–small cell lung cancer." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 9059. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9059.
Повний текст джерелаGutierrez, Catherine, Biagio Ricciuti, Joao Victor Machado Alessi, Federica Pecci, Adriana Paula de Castro Barrichello, Victor R. Vaz, Lynette M. Sholl, and Mark M. Awad. "Impact of STK11 copy loss on clinical outcomes to PD-(L)1 blockade in non–small cell lung cancer." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 9059. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9059.
Повний текст джерелаBhattacharya, Raka, Jeanne Kowalski, Allison R. Larson, Malcolm Brock, and Rhoda M. Alani. "Id1 Promotes Tumor Cell Migration in Nonsmall Cell Lung Cancers." Journal of Oncology 2010 (2010): 1–8. http://dx.doi.org/10.1155/2010/856105.
Повний текст джерелаGristina, Valerio, Maria La Mantia, Federica Iacono, Antonio Galvano, Antonio Russo, and Viviana Bazan. "The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer." Pharmaceuticals 13, no. 12 (December 18, 2020): 474. http://dx.doi.org/10.3390/ph13120474.
Повний текст джерелаPawelczyk, Konrad, Aleksandra Piotrowska, Urszula Ciesielska, Karolina Jablonska, Natalia Gletzel-Plucinska, Jedrzej Grzegrzolka, Marzenna Podhorska-Okolow, Piotr Dziegiel, and Katarzyna Nowinska. "Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers." International Journal of Molecular Sciences 20, no. 4 (February 14, 2019): 824. http://dx.doi.org/10.3390/ijms20040824.
Повний текст джерелаHonma, Rio, Ichiro Kinoshita, Eiji Miyoshi, Utano Tomaru, Yoshihiro Matsuno, Yasushi Shimizu, Satoshi Takeuchi, Kichizo Kaga, Naoyuki Taniguchi та Hirotoshi Akita. "Prognostic significance of α1,6-fucosyltransferase (α1,6-FT) in non-small cell lung cancers (NSCLCs)." Journal of Clinical Oncology 31, № 15_suppl (20 травня 2013): 7550. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7550.
Повний текст джерелаPyo, Jung-Soo, and Nae Yu Kim. "Clinicopathological Impact of the Spread through Air Space in Non-Small Cell Lung Cancer: A Meta-Analysis." Diagnostics 12, no. 5 (April 28, 2022): 1112. http://dx.doi.org/10.3390/diagnostics12051112.
Повний текст джерелаBorzi, Cristina, Giulia Galli, Monica Ganzinelli, Diego Signorelli, Claudio Vernieri, Marina Garassino, Gabriella Sozzi, and Massimo Moro. "Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment." Pharmaceuticals 13, no. 11 (November 13, 2020): 385. http://dx.doi.org/10.3390/ph13110385.
Повний текст джерелаLin, Yu-Shun, Yen-Chu Chen, Tzu-En Chen, Mei-Ling Cheng, Ke-Shiuan Lynn, Pramod Shah, Jin-Shing Chen, and Rwei-Fen S. Huang. "Probing Folate-Responsive and Stage-Sensitive Metabolomics and Transcriptional Co-Expression Network Markers to Predict Prognosis of Non-Small Cell Lung Cancer Patients." Nutrients 15, no. 1 (December 20, 2022): 3. http://dx.doi.org/10.3390/nu15010003.
Повний текст джерелаFumagalli, Caterina, Chiara Catania, Alberto Ranghiero, Carlo Bosi, Giuseppe Viale, Filippo de Marinis, Massimo Barberis, and Elena Guerini-Rocco. "Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients." Journal of Clinical Medicine 8, no. 1 (January 18, 2019): 112. http://dx.doi.org/10.3390/jcm8010112.
Повний текст джерелаTuononen, Katja, Virinder Kaur Sarhadi, Aino Wirtanen, Mikko Rönty, Kaisa Salmenkivi, Aija Knuuttila, Satu Remes, et al. "Targeted Resequencing RevealsALKFusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four Methods." BioMed Research International 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/757490.
Повний текст джерелаFarago, Anna F., Martin S. Taylor, Robert Charles Doebele, Alexander I. Spira, Theresa A. Boyle, Eric B. Haura, Roxana S. Azimi, Alice Tsang Shaw, Mari Mino-Kenudson, and Alexander E. Drilon. "Clinicopathologic features of non-small cell lung cancer (NSCLC) harboring an NTRK gene fusion." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 11580. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.11580.
Повний текст джерелаTamiya, Yutaro, Shingo Matsumoto, Takaya Ikeda, Kiyotaka Yoh, Terufumi Kato, Kazumi Nishino, Masahiro Kodani, et al. "Clinico-pathological and genomic features of NRAS- or HRAS-mutated non-small cell lung cancer (NSCLC) identified in large-scale genomic screening project (LC-SCRUM-Asia)." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 9054. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9054.
Повний текст джерелаCosta, Daniel Botelho, Hiroyuki Yasuda, Natasha J. Sng, Wee-Lee Yeo, Lorena Lobo de Figueiredo-Pontes, Daniel G. Tenen, and Susumu Kobayashi. "Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertion mutations within the tyrosine kinase domain of EGFR." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 7523. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.7523.
Повний текст джерелаCésaire, Mathieu, Juliette Montanari, Hubert Curcio, Delphine Lerouge, Radj Gervais, Pierre Demontrond, Jacques Balosso, and François Chevalier. "Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives." Cancers 14, no. 12 (June 8, 2022): 2829. http://dx.doi.org/10.3390/cancers14122829.
Повний текст джерелаEren, Bulent, Mehmet Sar, Buge Oz, and Fazilet H. Oner Dincbas. "MMP-2, TIMP-2 and CD44v6 Expression in Non-small-cell Lung Carcinomas." Annals of the Academy of Medicine, Singapore 37, no. 1 (January 15, 2008): 32–39. http://dx.doi.org/10.47102/annals-acadmedsg.v37n1p32.
Повний текст джерелаBang, Heejin, Mi-Sook Lee, Minjung Sung, Juyoung Choi, Sungbin An, Seok-Hyung Kim, Seung Eun Lee, and Yoon-La Choi. "NTRK Fusions in 1113 Solid Tumors in a Single Institution." Diagnostics 12, no. 6 (June 13, 2022): 1450. http://dx.doi.org/10.3390/diagnostics12061450.
Повний текст джерелаWatanabe, Satoshi, Kazuko Sakai, Naoya Matsumoto, Jun Koshio, Akira Ishida, Tetsuya Abe, Daisuke Ishikawa, et al. "Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)." Cancers 15, no. 1 (December 29, 2022): 204. http://dx.doi.org/10.3390/cancers15010204.
Повний текст джерелаKim, Jin Seuk, Haengbung Lee, Hojoong Kim, Young Mog Shim, Joungho Han, Joobae Park, and Duk-Hwan Kim. "Promoter Methylation of Retinoic Acid Receptor Beta 2 and the Development of Second Primary Lung Cancers in Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 22, no. 17 (September 1, 2004): 3443–50. http://dx.doi.org/10.1200/jco.2004.11.135.
Повний текст джерелаRicciuti, Biagio, Joao Victor Alessi, Xinan Wang, Arrien A. Bertram, Victor R. Vaz, Mizuki Nishino, James Lindsay, et al. "Abstract 2143: Clinicopathologic, genomic and immunophenotypic landscape of ATM mutations in non-small cell lung cancer." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2143. http://dx.doi.org/10.1158/1538-7445.am2022-2143.
Повний текст джерелаNehme, Eliana, Zahraa Rahal, Ansam Sinjab, Athar Khalil, Hassan Chami, Georges Nemer, and Humam Kadara. "Epigenetic Suppression of the T-box Subfamily 2 (TBX2) in Human Non-Small Cell Lung Cancer." International Journal of Molecular Sciences 20, no. 5 (March 7, 2019): 1159. http://dx.doi.org/10.3390/ijms20051159.
Повний текст джерелаChe, Nanying, Ziguang Xu, Yujie Dong, Peng Cheng, Yun Gao, Yang Yu, Shijun Fu, Min Gao, and Lingfei Kong. "Identification of MET Exon 14 skipping by targeted RNA-based next-generation sequencing in Chinese Patients with NSCLC." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e20018-e20018. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e20018.
Повний текст джерелаChoudhury, Noura J., Jaime Laurel Schneider, Tejas Patil, Viola Weijia Zhu, Debra A. Goldman, Soo-Ryum Yang, Christina Falcon, et al. "Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 9049. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9049.
Повний текст джерелаNishio, M., F. Ohyanagi, A. Horikike, Y. Ishikawa, Y. Satoh, S. Okumura, K. Nakagawa, K. Nishio, and T. Horai. "Serum levels of administered gefitinib correlate with the time to treatment failure in non small cell lung cancer patients." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 17027. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.17027.
Повний текст джерелаTakano, Atsushi, Yusuke Nakamura, and Yataro Daigo. "Identification of LASEP3 as a new serological and prognostic biomarker for lung and various type of cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e13565-e13565. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13565.
Повний текст джерелаLin, Emily Pei-Ying, Ching-Yao Yang, Ching-Wen Lin, Bo-Tsang Huang, Wei-Yun Lai, Yi-Ting Tseng, and Pan-Chyr Yang. "Priming PD-L1 expression by chemotherapeutic agents in non-small cell lung cancers." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e20087-e20087. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20087.
Повний текст джерелаAlessi, Joao Victor, Biagio Ricciuti, Yvonne Lin-Liu, Hersh Gupta, Xinan Wang, Giuseppe Lamberti, Gonzalo Recondo, et al. "67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A74—A75. http://dx.doi.org/10.1136/jitc-2021-sitc2021.067.
Повний текст джерела